4-ethyl-6-methylenandrosta-1,4-diene-3,17-dione | 107868-34-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 4-ethyl-6-methylenandrosta-1,4-diene-3,17-dione
• 英文别名: (8R,9S,10R,13S,14S)-4-ethyl-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
• CAS: 107868-34-8
• 化学式: C₂₂H₂₈O₂
• 分子量: 324.463
• InChiKey: WLWSBPBOCMIGEJ-IDRUFVAWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and aromatase inhibitors
  申请人：Lee G. Andrew

  公开号：US20050065126A1

  公开（公告）日：2005-03-24

  The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an aromatase inhibitor. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3 and an aromatase inhibitor.

  本发明涉及制药组合物和治疗方法，包括向需要的患者施用一种2-烷基亚基-19-去氢维生素D衍生物和一种芳香化酶抑制剂的组合物。特别地，本发明涉及制药组合物和治疗方法，包括向需要的患者施用2-亚甲基-19-去氢-20(S)-1α,25-二羟基维生素D3和一种芳香化酶抑制剂。
• PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND AN AROMATASE INHIBITOR
  申请人：Pfizer Products Inc.

  公开号：EP1937251A2

  公开（公告）日：2008-07-02
• US4808616A
  申请人：——

  公开号：US4808616A

  公开（公告）日：1989-02-28
• US4904650A
  申请人：——

  公开号：US4904650A

  公开（公告）日：1990-02-27
• [EN] PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND AROMATASE INHIBITORS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET METHODES DE TRAITEMENT CONSISTANT EN DES ASSOCIATIONS D'UN DERIVE DE LA 2-ALKYLIDENE-19-NOR-VITAMINE D ET D'UN INHIBITEUR DE L'AROMATASE
  申请人：PFIZER PROD INC

  公开号：WO2005027916A1

  公开（公告）日：2005-03-31

  The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an aromatase inhibitor. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 and an aromatase inhibitor.